|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,142.00 JPY | +0.21% |
|
+0.12% | +2.34% |
| 09:56pm | Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA | DJ |
| 07:35pm | Pfizer Poised for Mixed Second Quarter, RBC Says | MT |
| Market Cap | 3,837B 23.76B 20.78B 19.17B 17.7B 33.59B 2,266B 34.16B 229B 89.94B 1,116B 89.2B 87.26B | P/E 2027 * |
11.1x | P/E 2028 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3,761B 23.28B 20.36B 18.78B 17.35B 32.92B 2,221B 33.47B 224B 88.14B 1,094B 87.42B 85.52B | EV / Sales 2027 * |
1.67x | EV / Sales 2028 * | 1.66x |
| Free-Float |
97.66% | Yield 2027 * |
3.76% | Yield 2028 * | 3.86% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +0.21% | ||
| 1 week | +0.12% | ||
| Current month | -1.52% | ||
| 1 month | -0.12% | ||
| 3 months | -17.62% | ||
| 6 months | -4.23% | ||
| Current year | +2.34% |
| 1 week | 2,126 |  | 2,216.5 |
| 1 month | 2,041 | | 2,216.5 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,397.5 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Enyedy
BRD | Director/Board Member | 61 | 19/06/2025 |
Andreas Busch
BRD | Director/Board Member | 62 | 19/06/2025 |
Tomoko Aramaki
BRD | Director/Board Member | 57 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.21% | +0.12% | +54.55% | +3.93% | 23.58B | |
| -2.11% | -0.75% | +50.64% | +162.83% | 1,085B | |
| -0.99% | -1.01% | +62.79% | +60.94% | 624B | |
| -0.92% | -2.59% | +27.26% | +84.51% | 442B | |
| +0.33% | -1.17% | +27.98% | +26.90% | 332B | |
| -3.89% | -11.22% | +20.78% | +26.07% | 277B | |
| -0.02% | -2.85% | +25.27% | +44.88% | 282B | |
| +0.66% | -1.42% | -29.26% | -39.30% | 217B | |
| -0.07% | -0.72% | +21.11% | +61.88% | 196B | |
| -3.67% | +0.37% | +13.58% | +71.87% | 167B | |
| Average | -1.09% | -1.69% | +27.47% | +50.45% | 364.55B | |
| Weighted average by Cap. | -1.38% | -1.05% | +35.57% | +81.36% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,250B 13.93B 12.19B 11.24B 10.38B 19.7B 1,329B 20.03B 134B 52.74B 655B 52.31B 51.17B | 2,072B 12.83B 11.22B 10.35B 9.56B 18.13B 1,223B 18.44B 124B 48.55B 603B 48.16B 47.11B |
| Net income | 345B 2.13B 1.87B 1.72B 1.59B 3.02B 203B 3.07B 20.57B 8.08B 100B 8.01B 7.84B | 325B 2.01B 1.76B 1.62B 1.5B 2.84B 192B 2.89B 19.38B 7.61B 94.46B 7.55B 7.38B |
| Net Debt | -76.78B -475M -416M -384M -354M -672M -45.34B -683M -4.58B -1.8B -22.33B -1.78B -1.75B | -391B -2.42B -2.12B -1.95B -1.8B -3.42B -231B -3.48B -23.35B -9.17B -114B -9.09B -8.9B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/07/26 | ¥2,142.00 | +0.21% | 5,971,100 |
| 09/07/26 | ¥2,137.50 | -0.42% | 4,773,500 |
| 08/07/26 | ¥2,146.50 | -1.29% | 6,198,900 |
| 07/07/26 | ¥2,174.50 | -1.52% | 6,880,100 |
| 06/07/26 | ¥2,208.00 | +2.60% | 4,506,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
